Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) shares soared 24.74 percent to close at $4.74 a share Friday. The stock traded between $4.67 and $5.50 on volume of 8.02 million shares traded. The company announced that Sapacitabine has shown anti-tumor activity against ovarian cancer. Shares of Cyclacel Pharmaceuticals have fallen approximately 22.0 percent year-to-date.
Get more information on Cyclacel Pharmaceuticals and free access to the in-depth equity report at:
Prosensa Holding NV (NASDAQ: RNA) shares plunged 70.25 percent to close at $7.14 a share Friday. The stock traded between $5.65 and $8.00 on volume of 17.91 million shares traded. The company and GlaxoSmithKline announced that the primary endpoint was not met in a Phase II study of Drisapersen in patients with Duchenne Muscular Dystrophy.
Get more information on Prosensa and free access to the in-depth equity report at:
Retractable Technologies, Inc. (NYSEMKT: RVP) shares soared 71.67 percent to close at $3.09 a share Friday. The stock traded between $3.09 and $4.10 on volume of 1.63 million shares traded. The company announced that a Tyler, Texas jury has ruled in favor of their claims against industry giant Becton, Dickinson and Company. Shares of Retractable Technologies have gained approximately 255.0 percent year-to-date.
Get more information on Retractable Technologies and free access to the in-depth equity report at:
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares spiked 18.02 percent to close at $43.30 a share Friday. The stock traded between $36.07 and $46.16 on volume of 15.74 million shares traded. The company, who is also developing a treatment for Duchenne muscular dystrophy, looks to benefit from Prosena Holding and GlaxoSmithKline‘s recent announcement. Shares of Sarepta Therapeutics have gained approximately 68.0 percent year-to-date.
Get more information on Sarepta Therapeutics and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...